The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs

[1]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[2]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[3]  P. Workman.  Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. , 2003, Molecular cancer therapeutics.

[4]  P. Workman.  How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. , 2003, Current pharmaceutical design.

[5]  M. Sliwkowski,et al.  Preclinical studies with Erlotinib (Tarceva). , 2003, Seminars in oncology.

[6]  S. Steinberg,et al.  Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[8]  M. Phelps,et al.  Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  G. Powis,et al.  The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling , 2006, Cancer Chemotherapy and Pharmacology.

[10]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[11]  Elizabeth Garrett-Mayer,et al.  Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Bear,et al.  Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. , 2007, Nuclear medicine and biology.

[13]  J. Möcks,et al.  A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy , 2008, Clinical Cancer Research.

[14]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[15]  Roman K. Thomas,et al.  Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET) , 2008, PloS one.

[16]  C. Takimoto.  Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development. , 2009, European journal of cancer.

[17]  P. Workman,et al.  Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 , 2009, Molecular Cancer Therapeutics.

[18]  P. Workman,et al.  Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development , 2009, Cancer journal.

[19]  Dimitri Krainc,et al.  The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy. , 2010, Molecular cell.

[20]  M. Parmar,et al.  Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.

[21]  Paul Workman,et al.  Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.

[22]  R. Kerbel,et al.  Mouse models of advanced spontaneous metastasis for experimental therapeutics , 2011, Nature Reviews Cancer.

[23]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[24]  B. Morgan.  Opportunities and pitfalls of cancer imaging in clinical trials , 2011, Nature Reviews Clinical Oncology.

[25]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[26]  Oliver Langer,et al.  Approaches using molecular imaging technology -- use of PET in clinical microdose studies. , 2011, Advanced drug delivery reviews.

[27]  W. Hait.  Forty years of translational cancer research. , 2011, Cancer discovery.

[28]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[30]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[31]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[32]  C. Van de Wiele,et al.  Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases , 2012, British Journal of Cancer.

[33]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[34]  Qing‐Li Zhao,et al.  An in vivo molecular imaging probe 18F-Annexin B1 for apoptosis detection by PET/CT: preparation and preliminary evaluation , 2013, Apoptosis.

[35]  U. Banerji,et al.  Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials , 2012, Current drug targets.

[36]  N. Sharpless,et al.  Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. , 2012, The oncologist.

[37]  Giampaolo Tomasi,et al.  18F-ICMT-11, a Caspase-3–Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry , 2013, The Journal of Nuclear Medicine.

[38]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[39]  J. Kelm,et al.  A High-Throughput–Compatible 3D Microtissue Co-Culture System for Phenotypic RNAi Screening Applications , 2013, Journal of biomolecular screening.

[40]  S. Vacher,et al.  Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings , 2014, BMC Cancer.

[41]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[42]  Olav Engebraaten,et al.  Low‐molecular contrast agent dynamic contrast‐enhanced (DCE)‐MRI and diffusion‐weighted (DW)‐MRI in early assessment of bevacizumab treatment in breast cancer xenografts , 2013, Journal of magnetic resonance imaging : JMRI.

[43]  Andrew D J Pearson,et al.  How can attrition rates be reduced in cancer drug discovery? , 2013, Expert opinion on drug discovery.

[44]  Li Ding,et al.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.

[45]  Andreas Krieg,et al.  Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines , 2013, PloS one.

[46]  Klaus Pantel,et al.  Tumor metastasis: moving new biological insights into the clinic , 2013, Nature Medicine.

[47]  A. Jimeno,et al.  A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins , 2013, Molecular oncology.

[48]  D. Tuveson,et al.  Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer , 2013, PloS one.

[49]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[50]  J. Ware,et al.  First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[51]  Marcela Dávila López,et al.  Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions , 2014, Oncotarget.

[52]  Steven A. Soper,et al.  Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma , 2014, PloS one.

[53]  T. Yap,et al.  Circulating Tumor Cells: A Multifunctional Biomarker , 2014, Clinical Cancer Research.

[54]  S. Nicosia,et al.  One mouse, one patient paradigm: New avatars of personalized cancer therapy. , 2014, Cancer letters.

[55]  C. Shaw,et al.  Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis , 2015, Breast Cancer Research.

[56]  Tove Tuntland,et al.  Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research , 2014, Front. Pharmacol..

[57]  M. Jong,et al.  Imaging preclinical tumour models: improving translational power , 2014, Nature Reviews Cancer.

[58]  B. Ruggeri,et al.  Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. , 2014, Biochemical pharmacology.

[59]  Olivier Elemento,et al.  DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets , 2014, Nature chemical biology.

[60]  E. Mcwhinnie,et al.  DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells. , 2014, Nature chemical biology.

[61]  Darren Finlay,et al.  3-Dimensional Culture Systems for Anti-Cancer Compound Profiling and High-Throughput Screening Reveal Increases in EGFR Inhibitor-Mediated Cytotoxicity Compared to Monolayer Culture Systems , 2014, PloS one.

[62]  Liju Yang,et al.  Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. , 2014, Assay and drug development technologies.

[63]  C. Cordon-Cardo,et al.  Targeting cancer stem cells to suppress acquired chemotherapy resistance , 2014, Oncogene.

[64]  Zachary C. Dobbin,et al.  Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer , 2014, Oncotarget.

[65]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[66]  M. Junttila,et al.  Translational value of mouse models in oncology drug development , 2015, Nature Medicine.

[67]  J. Clohessy,et al.  Mouse hospital and co-clinical trial project—from bench to bedside , 2015, Nature Reviews Clinical Oncology.

[68]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[69]  Steven Piantadosi,et al.  Patient-centric trials for therapeutic development in precision oncology , 2015, Nature.

[70]  Chi-Ping Day,et al.  Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges , 2015, Cell.

[71]  H. Salvesen,et al.  Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma , 2015, PloS one.

[72]  N. Carragher,et al.  Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma , 2015, Cancer cell.

[73]  Camille Stephan-Otto Attolini,et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.

[74]  H. Ueno,et al.  Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer , 2015, Scientific Reports.

[75]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[76]  R. Scharpf,et al.  The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.

[77]  Xia Lou,et al.  High-Throughput Cancer Cell Sphere Formation for Characterizing the Efficacy of Photo Dynamic Therapy in 3D Cell Cultures , 2015, Scientific Reports.

[78]  Yixue Li,et al.  Integrated Analysis of Transcriptome in Cancer Patient-Derived Xenografts , 2015, PloS one.

[79]  Paul Workman,et al.  Critical parameters in targeted drug development: the pharmacological audit trail. , 2016, Seminars in oncology.

[80]  C. Taniguchi,et al.  Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia , 2016, Scientific Reports.

[81]  K. Reed,et al.  Organoids as a Model for Colorectal Cancer , 2016, Current Colorectal Cancer Reports.

[82]  Bruce A. Posner,et al.  Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.

[83]  Hanry Yu,et al.  Heralding a new paradigm in 3D tumor modeling. , 2016, Biomaterials.

[84]  A. Jimeno,et al.  Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. , 2016, Cancer research.

[85]  M. D. De Velasco,et al.  Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer , 2016, Oncotarget.

[86]  Bissan Al-Lazikani,et al.  Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines , 2016, Cell reports.

[87]  T. Sorg,et al.  Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice , 2016, Scientific Reports.

[88]  G. Mills,et al.  Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics , 2016, Clinical Cancer Research.

[89]  Sue Chua,et al.  High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. , 2016, Cancer discovery.

[90]  O. Muzik,et al.  Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma , 2016, Molecular imaging.

[91]  Nicolas André,et al.  Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.

[92]  Darjus F. Tschaharganeh,et al.  A Pipeline for Drug Target Identification and Validation , 2017, Cold Spring Harbor symposia on quantitative biology.

[93]  Jos Jonkers,et al.  Genetically engineered mouse models in oncology research and cancer medicine , 2016, EMBO molecular medicine.

[94]  Davide Prandi,et al.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.